HALO
Market read
The latest filing evidence is available. 0 of 4 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 20 directly disclosed connections are confirming.
Invalidation: The isolated read changes if HALO's group or a disclosed connection begins moving with it.
Research brief
The latest filing evidence is available. 0 of 4 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 20 directly disclosed connections are confirming.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
“Product Sales, Net – Product sales, net were as follows (in thousands): Six Months Ended Increase / (Decrease) June 30, 2026 2025 Dollar Percentage Proprietary product sales $ 97,301 $ 82,793 $ 14,508 18 % Bulk rHuPH20 sales 133,115 50,296 82,819 165 % Device…”10-Q · Aug 6, 2026 ↗
“Selling, General and Administrative – The increase in SG&A expenses was primarily due to an increase in consulting and professional service fees, including litigation costs in connection with a patent infringement litigation case, the acquisition of Elektrofi…”10-Q · Aug 6, 2026 ↗
“Income Tax Expense – Income tax expense was as follows (in thousands): Six Months Ended Increase / (Decrease) June 30, 2026 2025 Dollar Percentage Income tax expense $ 85,267 $ 65,511 $ 19,756 30 % The increase in income tax expense was primarily due to highe…”10-Q · Aug 6, 2026 ↗
“Interest Expense – Interest expense was as follows (in thousands): Six Months Ended Increase / (Decrease) June 30, 2026 2025 Dollar Percentage Interest expense $ 11,096 $ 8,919 $ 2,177 24 % The increase in interest expense is due to the issuance of the 2031 a…”10-Q · Aug 6, 2026 ↗
Valuation discipline
Price/sales 9.5× · EV/sales 10.9×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for HALO. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Latest filing assessment · baseline
10-Q filed 2026-05-11 against the comparable filing from 2025-05-06.
“The increase in cost of sales was primarily due to an increase in bulk rHuPH20 sales.”
“The increase in SG&A expenses was primarily due to an increase in consulting and professional service fees, including litigation costs in connection with a patent infringement litigation case, the acquisition of Elektrofi and Surf Bio, and an increase in compensation expense.”
“Product Sales, Net – Product sales, net were as follows (in thousands): Three Months Ended Increase / (Decrease) March 31, 2026 2025 Dollar Percentage Proprietary product sales $ 41,873 $ 36,341 $ 5,532 15 % Bulk rHuPH20 sales 73,497 27,025 46,472 172 % Device partnered product sales 15,054 14,675 379 3 % Total product sales, net $ 130,424 $ 78,041 $ 52,383 67 % The increase in product sales, net was primarily due to increased sales of bulk rHuPH20 driven by partner demand as well as contributions from our proprietary product XYOSTED driven by continued market growth.”
Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
“We have commercialized auto-injector products with Teva Pharmaceutical Industries, Ltd.”
“13 Table of Contents Pfizer Collaboration In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Pfizer proprieta…”
Depended on by
“On May 1, 2026, the Company and Halozyme Hypercon, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 21 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
HALO is currently a Early Follower in the organic co-movement group Growth Stocks. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
No durable theme membership has been observed for this name yet.